You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 23, 2024

Claims for Patent: 9,492,506

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,492,506

Title:	Oligonucleotide chelate complex--polypeptide compositions and methods
Abstract:	It is disclosed a pharmaceutical composition containing an oligonuclelotide chelate complex and at least one polypeptide or pegylated polypeptide. The present disclosure also describes additional pharmaceutical compositions and methods for the treatment of diseases including viral infections.
Inventor(s):	Bazinet; Michel (Montreal, CA), Vaillant; Andrew (Roxboro, CA)
Assignee:	REPLICOR INC. (Montreal, CA)
Application Number:	13/896,510
Patent Claims:	1. A pharmaceutical composition comprising an oligonucleotide (ON) chelate complex, consisting of two or more ONs linked intermolecularly by a divalent cation, and at least one of: Thymosin .alpha.1; Any .alpha.-interferon or pegylated derivatives thereof; Any .beta.-interferon or pegylated derivatives thereof; Any .gamma.-interferon or pegylated derivatives thereof; Any .lamda.-interferon or pegylated derivatives thereof; Interferon .alpha.-2a or .alpha.-2b or .alpha.-N3; Interferon .beta.-1a or .beta.-1b; Interferon .gamma.-1b; Interferon .lamda.1 or .lamda.2 or .lamda.3; Pegylated interferon .alpha.-2a or .alpha.-2b or .lamda.1 or .lamda.2 or .lamda.3; Myrcludex B; Any antiviral cytokine or pegylated derivatives thereof; and Thymic protein A. 2. A pharmaceutical composition comprising an antiviral ON chelate complex, consisting of two or more antiviral ONs linked intermolecularly by a divalent cation, and at least one antiviral of: Thymosin .alpha.1; Any .alpha.-interferon or pegylated derivatives thereof; Any .beta.-interferon or pegylated derivatives thereof; Any .gamma.-interferon or pegylated derivatives thereof; Any .lamda.-interferon or pegylated derivatives thereof; Interferon .alpha.-2a or .alpha.-2b or .alpha.-N3; Interferon .beta.-1a or .beta.-1b; Interferon .gamma.-1b; Interferon .lamda.1 or .lamda.2 or .lamda.3; Pegylated interferon .alpha.-2a or .alpha.-2b or .lamda.1 or .lamda.2 or .lamda.3; Myrcludex B; Any antiviral cytokine or peqylated derivatives thereof; and Thymic protein A. 3. The pharmaceutical composition of claim 1 or 2, wherein said divalent metal cation is calcium. 4. The pharmaceutical composition of claim 1 or 2, wherein said divalent metal cation is magnesium. 5. The pharmaceutical composition of claim 1 or 2, wherein said divalent metal cation is iron (2+), manganese, copper or zinc. 6. The pharmaceutical composition of claim 1 or 2, wherein said divalent cation is comprised of two or more different divalent metal cations. 7. The pharmaceutical composition of claim 1 or 2, wherein said divalent cation is comprised of calcium and magnesium. 8. The pharmaceutical composition of claim 1 or 2, wherein said ON chelate complex comprises at least one double stranded ON. 9. The pharmaceutical composition of claim 1 or 2, wherein said ON chelate complex comprises at least one ON with at least one phosphorothioate linkage. 10. The pharmaceutical composition of claim 1 or 2, wherein said ON chelate complex comprises at least one fully phosphorothioated ON. 11. The pharmaceutical composition of claim 1 or 2, wherein said ON chelate complex comprises at least one ON with one 2' modified ribose. 12. The pharmaceutical composition of claim 1 or 2, wherein said ON chelate complex comprises at least one ON which has each ribose 2' O-methylated. 13. The pharmaceutical composition of claim 1 or 2, wherein said ON chelate complex comprises at least one ON comprising at least one 5'methylcytosine. 14. The pharmaceutical composition of claim 1 or 2, wherein said ON chelate complex comprises at least one ON in which each cytosine is further 5'methylcytosine. 15. The pharmaceutical composition of claim 1 or 2, wherein said ON chelate complex comprises at least one ON in which every ribose is 2' O-methylated and in which each cytosine is further 5'methylcytosine. 16. The pharmaceutical composition of claim 1 or 2, wherein said ON chelate complex comprises an oligonucleotide selected from SEQ ID NOs: 1-6 and 10-18. 17. The pharmaceutical composition of claim 1 or 2, wherein said ON chelate complex comprises an oligonucleotide selected from SEQ ID NOs: 7-9. 18. The pharmaceutical composition of claim 1 or 2, formulated for subcutaneous administration. 19. The pharmaceutical composition of claim 1 or 2, formulated for intravenous infusion. 20. The pharmaceutical composition of claim 1 or 2, formulated for at least one of the following routes of administration: aerosol inhalation, intraocular, oral ingestion, enteric, intramuscular injection, intraperitoneal injection, intrathecal injection, intrathecal infusion, intratracheal, intravenous injection and topically. 21. The pharmaceutical composition of claim 1 or 2, wherein said ON chelate complex comprises at least one ON consisting of SEQ ID NO: 2. 22. The pharmaceutical composition of claim 1 or 2, wherein said ON chelate complex comprises at least one ON consisting of SEQ ID NO: 11. 23. The pharmaceutical composition of claim 1 or 2, wherein said wherein said ON chelate complex comprises at least one ON consisting of SEQ ID NO: 18. 24. The pharmaceutical composition of claim 1 or 2, further comprising one or more of the following: entecavir, tenofovir disoproxil fumarate, telbuvidine, adefovir dipivoxil, lamivudine, ribavirin, telaprevir, boceprevir, GS-7977, tegobuvir, zanamivir, oseltamivir, ganciclovir, foscarnet, acyclovir, zidovudine, abacavir, lopinavir, ritonavir or efavirenz. 25. The pharmaceutical composition of claim 1 or 2, further comprising a carrier. 26. A pharmaceutical composition comprising an ON chelate complex comprising an oligonucleotide consisting of SEQ ID NO: 3, and pegylated interferon .alpha.-2a. 27. A pharmaceutical composition comprising an ON chelate complex consisting of two or more ONs linked intermolecularly by a divalent cation, comprising at least one oligonucleotide consisting of SEQ ID NO: 18, and pegylated interferon .alpha.-2a. 28. A pharmaceutical composition comprising an ON chelate complex comprising an oligonucleotide consisting of SEQ ID NO: 11, and pegylated interferon .alpha.-2a. 29. A pharmaceutical composition comprising an ON chelate complex comprising an oligonucleotide consisting of SEQ ID NO: 3, and thymosin .alpha.1. 30. A pharmaceutical composition comprising an ON chelate complex comprising an oligonucleotide consisting of SEQ ID NO: 18, and thymosin .alpha.1. 31. A pharmaceutical composition comprising an ON chelate complex comprising an oligonucleotide consisting of SEQ ID NO: 11, and thymosin .alpha.1. 32. A pharmaceutical composition comprising an ON chelate complex comprising an oligonucleotide consisting of SEQ ID NO: 2, and interferon .alpha.-2b. 33. A pharmaceutical composition comprising an ON chelate complex consisting of two or more ONs linked intermolecularly by a divalent cation, comprising at least one oligonucleotide consisting of SEQ ID NO: 18, and interferon .alpha.-2b. 34. A pharmaceutical composition comprising an ON chelate complex comprising an oligonucleotide consisting of SEQ ID NO: 11, and interferon .alpha.-2b. 35. A pharmaceutical composition comprising an ON chelate complex comprising an oligonucleotide consisting of SEQ ID NO: 3, and pegylated thymosin .alpha.1. 36. A pharmaceutical composition comprising an ON chelate complex comprising an oligonucleotide consisting of SEQ ID NO: 18, and pegylated thymosin .alpha.1. 37. A pharmaceutical composition comprising an ON chelate complex comprising an oligonucleotide consisting of SEQ ID NO: 11, and pegylated thymosin .alpha.1. 38. A pharmaceutical composition comprising an ON chelate complex comprising an oligonucleotide consisting of SEQ ID NO: 3, and pegylated interferon .alpha.-2b. 39. A pharmaceutical composition comprising an ON chelate complex consisting of two or more ONs linked intermolecularly by a divalent cation, comprising an oligonucleotide consisting of SEQ ID NO: 18, and pegylated interferon .alpha.-2b. 40. A pharmaceutical composition comprising an ON chelate complex comprising an oligonucleotide consisting of SEQ ID NO: 11, and pegylated interferon .alpha.-2b. 41. A pharmaceutical composition comprising an ON chelate complex comprising an oligonucleotide consisting of SEQ ID NO: 3, and interferon .lamda.1. 42. A pharmaceutical composition comprising an ON chelate complex comprising an oligonucleotide consisting of SEQ ID NO: 18, and interferon .lamda.1. 43. A pharmaceutical composition comprising an ON chelate complex comprising an oligonucleotide consisting of SEQ ID NO: 11, and interferon .lamda.1. 44. A pharmaceutical composition comprising an ON chelate complex comprising an oligonucleotide consisting of SEQ ID NO: 3, and pegylated interferon .lamda.1. 45. A pharmaceutical composition comprising an ON chelate complex comprising an oligonucleotide consisting of SEQ ID NO: 18, and pegylated interferon .lamda.1. 46. A pharmaceutical composition comprising an ON chelate complex comprising an oligonucleotide consisting of SEQ ID NO: 11, and pegylated interferon .lamda.1.

Details for Patent 9,492,506

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Biogen Inc.	AVONEX	interferon beta-1a	For Injection	103628	05/17/1996	⤷ Try a Trial	2032-05-18
Biogen Inc.	AVONEX	interferon beta-1a	Injection	103628	05/28/2003	⤷ Try a Trial	2032-05-18
Biogen Inc.	AVONEX	interferon beta-1a	Injection	103628	02/27/2012	⤷ Try a Trial	2032-05-18
Emd Serono, Inc.	REBIF	interferon beta-1a	Injection	103780	03/07/2002	⤷ Try a Trial	2032-05-18
Emd Serono, Inc.	REBIF	interferon beta-1a	Injection	103780	12/17/2004	⤷ Try a Trial	2032-05-18
Emd Serono, Inc.	REBIF	interferon beta-1a	Injection	103780	12/21/2012	⤷ Try a Trial	2032-05-18
Horizon Therapeutics Ireland Dac	ACTIMMUNE	interferon gamma-1b	Injection	103836	02/25/1999	⤷ Try a Trial	2032-05-18
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.